Remission & chronicity
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.
ABCG2
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| FOLIC ACID | ? unclear | Mechanistic | DGIdb | |
| VORICONAZOLE | ? unclear | Mechanistic | DGIdb | |
| AXITINIB | ? unclear | Mechanistic | DGIdb | |
| OSIMERTINIB | ? unclear | Mechanistic | DGIdb | |
| FELODIPINE | ? unclear | Mechanistic | DGIdb | |
| TOPOTECAN HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| TELMISARTAN | ? unclear | Mechanistic | DGIdb | |
| DELAVIRDINE | ? unclear | Mechanistic | DGIdb | |
| SIROLIMUS | ? unclear | Mechanistic | DGIdb | |
| SILYMARIN | ? unclear | Mechanistic | DGIdb | |
| CYCLOSPORINE | ↓ inhibits | Mechanistic | 63095.73 nM (IC50) | DGIdb |
| ALVOCIDIB | ? unclear | Mechanistic | DGIdb | |
| ANHYDROUS TACROLIMUS | ? unclear | Mechanistic | DGIdb | |
| CYCLOPHOSPHAMIDE ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| TENOFOVIR | ? unclear | Mechanistic | DGIdb | |
| ERLOTINIB HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| PACLITAXEL | ? unclear | Mechanistic | DGIdb | |
| HUMAN CHORIONIC GONADOTROPIN | ? unclear | Mechanistic | DGIdb | |
| ERLOTINIB | ? unclear | Mechanistic | DGIdb | |
| EFAVIRENZ | ? unclear | Mechanistic | DGIdb | |
| DOLUTEGRAVIR SODIUM | ? unclear | Mechanistic | DGIdb | |
| IGURATIMOD | ? unclear | Mechanistic | DGIdb | |
| SORAFENIB | ? unclear | Mechanistic | DGIdb | |
| KETOCONAZOLE | ? unclear | Mechanistic | DGIdb | |
| ELACRIDAR | ? unclear | Mechanistic | 410.0 nM (IC50) | DGIdb |
| PRASTERONE | ? unclear | Mechanistic | DGIdb | |
| RHODAMINE123 | ? unclear | Mechanistic | DGIdb | |
| PRAZOSIN | ? unclear | Mechanistic | DGIdb | |
| PRAVASTATIN SODIUM | ? unclear | Mechanistic | DGIdb | |
| DOXORUBICIN HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| SN-38 | ? unclear | Mechanistic | DGIdb | |
| IMATINIB | ? unclear | Mechanistic | 4897.79 nM (IC50) | DGIdb |
| RISPERIDONE | ? unclear | Mechanistic | DGIdb | |
| FLUVASTATIN | ? unclear | Mechanistic | DGIdb | |
| ZIDOVUDINE | ? unclear | Mechanistic | DGIdb | |
| NILOTINIB | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL428402 | ? unclear | Mechanistic | DGIdb | |
| LOVASTATIN | ? unclear | Mechanistic | DGIdb | |
| ITRACONAZOLE | ? unclear | Mechanistic | DGIdb | |
| DIFLOMOTECAN | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 188 agents ranked by evidence tier.
IL1B
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| ASPIRIN | ? unclear | Mechanistic | DGIdb | |
| MAFOSFAMIDE | ? unclear | Mechanistic | DGIdb | |
| DIACETYLRHEIN | ? unclear | Mechanistic | DGIdb | |
| INFLIXIMAB | ? unclear | Mechanistic | DGIdb | |
| LANSOPRAZOLE | ? unclear | Mechanistic | DGIdb | |
| TILUDRONIC ACID | ? unclear | Mechanistic | DGIdb | |
| GEVOKIZUMAB | ~ modulates | Mechanistic | DGIdb | |
| LUTIKIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| CELASTROL | ? unclear | Mechanistic | DGIdb | |
| CYTARABINE | ? unclear | Mechanistic | DGIdb | |
| RILONACEPT | ↓ inhibits | Mechanistic | DGIdb | |
| TT-301 | ? unclear | Mechanistic | DGIdb | |
| METFORMIN | ? unclear | Mechanistic | DGIdb | |
| ANTICONVULSANT AGENT | ? unclear | Mechanistic | DGIdb | |
| ANTIDEPRESSANT AGENT | ? unclear | Mechanistic | DGIdb | |
| ACITRETIN | ? unclear | Mechanistic | DGIdb | |
| ERYTHROMYCIN | ? unclear | Mechanistic | DGIdb | |
| ALTEPLASE | ? unclear | Mechanistic | DGIdb | |
| OFLOXACIN | ? unclear | Mechanistic | DGIdb | |
| PENTOXIFYLLINE | ? unclear | Mechanistic | DGIdb | |
| USTEKINUMAB | ? unclear | Mechanistic | DGIdb | |
| LITHIUM | ? unclear | Mechanistic | DGIdb | |
| RALOXIFENE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| MITOGEN-ACTIVATED PROTEIN KINASE INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| DRUGSATFDA.NDA:008378 | ? unclear | Mechanistic | DGIdb | |
| NICARDIPINE | ? unclear | Mechanistic | DGIdb | |
| GLUCOSAMINE | ? unclear | Mechanistic | DGIdb | |
| BECLOMETHASONE DIPROPIONATE | ? unclear | Mechanistic | DGIdb | |
| PAREGORIC | ? unclear | Mechanistic | DGIdb | |
| CEFACLOR ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| IBUDILAST | ? unclear | Mechanistic | DGIdb | |
| MELATONIN | ? unclear | Mechanistic | DGIdb | |
| PENTAMIDINE | ? unclear | Mechanistic | DGIdb | |
| PRAVASTATIN SODIUM | ? unclear | Mechanistic | DGIdb | |
| VERAPAMIL | ? unclear | Mechanistic | DGIdb | |
| THYROGLOBULIN | ? unclear | Mechanistic | DGIdb | |
| RISEDRONIC ACID | ? unclear | Mechanistic | DGIdb | |
| AUTOANTIGEN | ? unclear | Mechanistic | DGIdb | |
| CDP-484 | ↓ inhibits | Mechanistic | DGIdb | |
| ETIDRONIC ACID | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 218 agents ranked by evidence tier.
NLRP3
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| ANAKINRA | ? unclear | Mechanistic | DGIdb | |
| ALAPROCLATE HYDROCHLORIDE | ? unclear | Mechanistic | 8020.0 nM (IC50) | DGIdb |
| ENCLOMIPHENE CITRATE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL585591 | ? unclear | Mechanistic | DGIdb | |
| 4'-METHOXYFLAVONE | ? unclear | Mechanistic | 31000.0 nM (IC50) | DGIdb |
| DAPANSUTRILE | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL602526 | ? unclear | Mechanistic | DGIdb | |
| TRICLOCARBAN | ? unclear | Mechanistic | 1490.0 nM (IC50) | DGIdb |
| CLIOXANIDE | ? unclear | Mechanistic | 1610.0 nM (IC50) | DGIdb |
| CHEMBL1336269 | ↓ inhibits | Mechanistic | 8010.0 nM (IC50) | ChEMBL |
| CHEMBL1596681 | ↓ inhibits | Mechanistic | 9020.0 nM (IC50) | ChEMBL |
| CHEMBL1447078 | ↓ inhibits | Mechanistic | 53900.0 nM (IC50) | ChEMBL |
| CHEMBL1457403 | ↓ inhibits | Mechanistic | 4790.0 nM (IC50) | ChEMBL |
| CHEMBL1539913 | ↓ inhibits | Mechanistic | 35400.0 nM (IC50) | ChEMBL |
| CHEMBL1366588 | ↓ inhibits | Mechanistic | 2070.0 nM (IC50) | ChEMBL |
| CHEMBL1709001 | ↓ inhibits | Mechanistic | 14900.0 nM (IC50) | ChEMBL |
| CHEMBL1329507 | ↓ inhibits | Mechanistic | 11000.0 nM (IC50) | ChEMBL |
| CHEMBL1507547 | ↓ inhibits | Mechanistic | 76600.0 nM (IC50) | ChEMBL |
| CLOMIPHENE | ↓ inhibits | Mechanistic | 29300.0 nM (IC50) | ChEMBL |
| CHEMBL1339092 | ↓ inhibits | Mechanistic | 11700.0 nM (IC50) | ChEMBL |
| CHEMBL1574982 | ↓ inhibits | Mechanistic | 3530.0 nM (IC50) | ChEMBL |
| CHEMBL1558285 | ↓ inhibits | Mechanistic | 14300.0 nM (IC50) | ChEMBL |
| CHEMBL3193158 | ↓ inhibits | Mechanistic | 7300.0 nM (IC50) | ChEMBL |
| CHEMBL1339245 | ↓ inhibits | Mechanistic | 9700.0 nM (IC50) | ChEMBL |
| CHEMBL1386774 | ↓ inhibits | Mechanistic | 4910.0 nM (IC50) | ChEMBL |
| CHEMBL1412902 | ↓ inhibits | Mechanistic | 10300.0 nM (IC50) | ChEMBL |
| CHEMBL1347185 | ↓ inhibits | Mechanistic | 6600.0 nM (IC50) | ChEMBL |
| CHEMBL1343658 | ↓ inhibits | Mechanistic | 1940.0 nM (IC50) | ChEMBL |
| CHEMBL1602195 | ↓ inhibits | Mechanistic | 2900.0 nM (IC50) | ChEMBL |
| CHEMBL1334557 | ↓ inhibits | Mechanistic | 5920.0 nM (IC50) | ChEMBL |
| CHEMBL1711405 | ↓ inhibits | Mechanistic | 23300.0 nM (IC50) | ChEMBL |
| CHEMBL3192672 | ↓ inhibits | Mechanistic | 45500.0 nM (IC50) | ChEMBL |
| CHEMBL1563728 | ↓ inhibits | Mechanistic | 3160.0 nM (IC50) | ChEMBL |
| CHEMBL1505335 | ↓ inhibits | Mechanistic | 41800.0 nM (IC50) | ChEMBL |
| CHEMBL1447669 | ↓ inhibits | Mechanistic | 8190.0 nM (IC50) | ChEMBL |
| CHEMBL1427059 | ↓ inhibits | Mechanistic | 1970.0 nM (IC50) | ChEMBL |
| CHEMBL1505307 | ↓ inhibits | Mechanistic | 43400.0 nM (IC50) | ChEMBL |
| CHEMBL602526 | ↓ inhibits | Mechanistic | 1620.0 nM (IC50) | ChEMBL |
| CHEMBL1398317 | ↓ inhibits | Mechanistic | 13700.0 nM (IC50) | ChEMBL |
| CHEMBL3191011 | ↓ inhibits | Mechanistic | 24300.0 nM (IC50) | ChEMBL |
Showing top 40 of 138 agents ranked by evidence tier.
SLC22A12
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| VERINURAD | ↓ inhibits | Mechanistic | 23.0 nM (IC50) | DGIdb |
| ARHALOFENATE | ↓ inhibits | Mechanistic | DGIdb | |
| PRATOSARTAN | ↓ inhibits | Mechanistic | DGIdb | |
| IDARUBICIN | ? unclear | Mechanistic | DGIdb | |
| DOTINURAD | ↓ inhibits | Mechanistic | DGIdb | |
| BENZBROMARONE | ↓ inhibits | Mechanistic | 300.0 nM (IC50) | DGIdb |
| LOSARTAN POTASSIUM | ? unclear | Mechanistic | DGIdb | |
| SHR-4640 | ↓ inhibits | Mechanistic | 33.7 nM (IC50) | DGIdb |
| FLUDARABINE | ? unclear | Mechanistic | DGIdb | |
| GEMTUZUMAB OZOGAMICIN | ? unclear | Mechanistic | DGIdb | |
| CYTARABINE | ? unclear | Mechanistic | DGIdb | |
| LESINURAD | ↓ inhibits | Mechanistic | 6700.0 nM (IC50) | DGIdb |
| SULFINPYRAZONE | ↓ inhibits | Mechanistic | 100000.0 nM (IC50) | DGIdb |
| MORIN | ↓ inhibits | Mechanistic | 2000.0 nM (IC50) | ChEMBL |
| PROBENECID | ↓ inhibits | Mechanistic | 50000.0 nM (IC50) | ChEMBL |
| CHEMBL1767090 | ↓ inhibits | Mechanistic | 2490.0 nM (IC50) | ChEMBL |
| CHEMBL1767088 | ↓ inhibits | Mechanistic | 2460.0 nM (IC50) | ChEMBL |
| BENZARONE | ↓ inhibits | Mechanistic | 2800.0 nM (IC50) | ChEMBL |
| CHEMBL1767079 | ↓ inhibits | Mechanistic | 138.0 nM (IC50) | ChEMBL |
| CHEMBL1767091 | ↓ inhibits | Mechanistic | 6680.0 nM (IC50) | ChEMBL |
| CHEMBL1767094 | ↓ inhibits | Mechanistic | 33650.0 nM (IC50) | ChEMBL |
| CHEMBL1767097 | ↓ inhibits | Mechanistic | 3920.0 nM (IC50) | ChEMBL |
| CHEMBL1767099 | ↓ inhibits | Mechanistic | 1130.0 nM (IC50) | ChEMBL |
| CHEMBL1767100 | ↓ inhibits | Mechanistic | 19690.0 nM (IC50) | ChEMBL |
| CHEMBL1767105 | ↓ inhibits | Mechanistic | 3940.0 nM (IC50) | ChEMBL |
| CHEMBL1767106 | ↓ inhibits | Mechanistic | 42.0 nM (IC50) | ChEMBL |
| CHEMBL1767107 | ↓ inhibits | Mechanistic | 189.0 nM (IC50) | ChEMBL |
| CHEMBL1767108 | ↓ inhibits | Mechanistic | 358.0 nM (IC50) | ChEMBL |
| CHEMBL1767109 | ↓ inhibits | Mechanistic | 83.0 nM (IC50) | ChEMBL |
| CHEMBL1767110 | ↓ inhibits | Mechanistic | 1440.0 nM (IC50) | ChEMBL |
| CHEMBL1767111 | ↓ inhibits | Mechanistic | 287.0 nM (IC50) | ChEMBL |
| CHEMBL1767112 | ↓ inhibits | Mechanistic | 111.0 nM (IC50) | ChEMBL |
| CHEMBL1767113 | ↓ inhibits | Mechanistic | 1650.0 nM (IC50) | ChEMBL |
| CHEMBL1767114 | ↓ inhibits | Mechanistic | 177.0 nM (IC50) | ChEMBL |
| CHEMBL1767115 | ↓ inhibits | Mechanistic | 23460.0 nM (IC50) | ChEMBL |
| CHEMBL1767116 | ↓ inhibits | Mechanistic | 667.0 nM (IC50) | ChEMBL |
| CHEMBL1767117 | ↓ inhibits | Mechanistic | 772.0 nM (IC50) | ChEMBL |
| CHEMBL3745776 | ↓ inhibits | Mechanistic | 158.8 nM (IC50) | ChEMBL |
| CHEMBL3745813 | ↓ inhibits | Mechanistic | 1189.0 nM (IC50) | ChEMBL |
| CHEMBL3747053 | ↓ inhibits | Mechanistic | 333.4 nM (IC50) | ChEMBL |
Showing top 40 of 200 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| THERAPEUTIC GLUCOCORTICOID | ? unclear | Mechanistic | DGIdb | |
| MERCAPTOPURINE | ? unclear | Mechanistic | DGIdb | |
| QUERCETIN | ? unclear | Mechanistic | 3000.0 nM (IC50) | DGIdb |
| DIDANOSINE | ? unclear | Mechanistic | DGIdb | |
| INSULIN, REGULAR, HUMAN | ? unclear | Mechanistic | DGIdb | |
| BENZODIAZEPINE | ? unclear | Mechanistic | DGIdb | |
| DOXORUBICIN HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| ROXITHROMYCIN | ? unclear | Mechanistic | DGIdb | |
| FEBUXOSTAT | ↓ inhibits | Mechanistic | 30.0 nM (IC50) | DGIdb |
| IMMUNOTHERAPEUTIC AGENT | ? unclear | Mechanistic | DGIdb | |
| FOSDENOPTERIN | ? unclear | Mechanistic | DGIdb | |
| FENTANYL CITRATE | ? unclear | Mechanistic | DGIdb | |
| ALLOPURINOL | ↓ inhibits | Mechanistic | 4200.0 nM (IC50) | DGIdb |
| ALLOPURINOL SODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| VINCRISTINE | ? unclear | Mechanistic | DGIdb | |
| PAPAVERINE | ? unclear | Mechanistic | DGIdb | |
| RICIN | ? unclear | Mechanistic | DGIdb | |
| RECOMBINANT INTERFERON | ? unclear | Mechanistic | DGIdb | |
| FOLIC ACID | ? unclear | Mechanistic | DGIdb | |
| AZITHROMYCIN ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| CHEMOPREVENTIVE AGENT | ? unclear | Mechanistic | DGIdb | |
| METHYLENE BLUE ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| TIGULIXOSTAT | ? unclear | Mechanistic | DGIdb | |
| ERYTHROMYCIN | ? unclear | Mechanistic | DGIdb | |
| CARVEDILOL | ? unclear | Mechanistic | DGIdb | |
| MISONIDAZOLE | ? unclear | Mechanistic | DGIdb | |
| SIALYL TN ANTIGEN | ? unclear | Mechanistic | DGIdb | |
| CURCUMIN | ? unclear | Mechanistic | DGIdb | |
| NITROFURANTOIN, MACROCRYSTALS | ? unclear | Mechanistic | DGIdb | |
| HYPOXANTHINE | ? unclear | Mechanistic | DGIdb | |
| MITOMYCIN | ? unclear | Mechanistic | DGIdb | |
| THIOGUANINE | ? unclear | Mechanistic | 92420.0 nM (IC50) | DGIdb |
| DAUNORUBICIN LIPOSOMAL | ? unclear | Mechanistic | DGIdb | |
| OXYPURINOL | ↓ inhibits | Mechanistic | 1000.0 nM (Ki) | DGIdb |
| CHINESE HERBS | ? unclear | Mechanistic | DGIdb | |
| TOPIROXOSTAT | ↓ inhibits | Mechanistic | DGIdb | |
| BENDAZAC | ↓ inhibits | Mechanistic | DGIdb | |
| OTERACIL POTASSIUM | ? unclear | Mechanistic | DGIdb | |
| CLARITHROMYCIN | ? unclear | Mechanistic | DGIdb | |
| CHEMBL87562 | ↓ inhibits | Mechanistic | 330.0 nM (Ki) | ChEMBL |
Showing top 40 of 189 agents ranked by evidence tier.
Clinical Trials
Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Gout: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.
The primary objective of this trial is to evaluate the effect of pegloticase 18 mg subcutaneously (SC) every two weeks with methotrexate (MTX) versus pegloticase 8 mg intravenously (IV) every two weeks with MTX on the response rate during Month 6, as measured by the sustained normalization of serum ...
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
The most frequent crystal arthropathy is gout, which is also the most prevalent cause of inflammatory arthritis. Gouty Patients frequently have excruciating pain and swelling in their joints. Gout is linked to decreased health-related quality of life and functional disability. Gout and its associate...
This is a multicenter, randomized, double-blind, placebo-controlled phase II study assessing the efficacy, safety, and dosing regimen selection of multiple IV infusions of PRX-115 over 24 weeks, with or without MTX, versus the respective placebos in adult patients with gout.
The primary objective of this trial is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 in participants with gout who are XOI intolerant or have failed uricase treatment.
The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with tophaceous gout.
The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with hyperuricemia associated with gout.
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Gout is a systemic disease that results from the deposition of monosodium urate crystals (MSU) in tissues. Increased serum uric acid (SUA) above a specific threshold (\>6.8 mg/dl) is a requirement for the formation of uric acid crystals. MSU crystals can be deposited in all tissues mainly in and aro...
The study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of pegloticase Q4W with MTX versus pegloticase Q2W with MTX, followed by a 24-week open-label extension of pegloticase Q4W with MTX, in participants with uncontrolled refractory gout. The main...
The primary purpose of this study is to compare the efficacy of Tigulixostat (IBI128) versus Febuxostat on the proportion of Chinese adults with gout achieving a serum uric acid (sUA) level \< 360 μmol/L at Week 24. The study also evaluates safety, gout attacks, kidney function, inflammation, and qu...
Study YDHY (HZBio1)-001 (Ib/Ⅱ) is an open-label, dose-escalation and expansion, multicenter Phase Ib/II clinical trial conducted in China. The primary objectives were to evaluate the safety, tolerability, and PK of multiple-dose administration of HZBio1. The secondary objectives were to preliminaril...
SAVE-Care (Sodium Glucose Cotransporter-2 inhibitors \[SGLT2i\] As Novel Gout Care) Trial is a double-blind randomized placebo-controlled trial (RCT) designed to assess the effect of empagliflozin on serum urate \[SU\] levels of gout patients, as well as levels of highly-sensitivity C-reactive prote...
The goal of this clinical study is to learn if IN026 Injection is safe and works to lower uric acid levels in adults with refractory gout (gout that does not respond well to standard treatments). The main questions it aims to answer are: * What medical problems do participants have when taking IN026...
The study is to evaluate the impact of food on the pharmacokinetics of F-02-2-Na in healthy adult subjects by observing the changes in the drug's pharmacokinetic profile-particularly in its absorption process-before and after food intake.
Agents Found By Disease-Level Search
Searched directly from “Gout” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 5-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).
55 agents shown (approved or with trial evidence) — 46 not found by the gene-target search above.
Febuxostat
allopurinol
PegloticaseNOT in gene-target list
Canakinumab
ColchicineNOT in gene-target list
Lesinurad
dotinurad
Arhalofenate
MethotrexateNOT in gene-target list
Colchicine 0.6 mgNOT in gene-target list
ABP-671NOT in gene-target list
Allopurinol 300 mgNOT in gene-target list
dotinurad (FYU-981)NOT in gene-target list
Triamcinolone acetonideNOT in gene-target list
Canakinumab 150 mgNOT in gene-target list
Triamcinolone acetonide 40 mgNOT in gene-target list
Placebo to canakinumabNOT in gene-target list
Placebo to triamcinolone acetonideNOT in gene-target list
Rilonacept
Pegloticase 8 MG/ML [Krystexxa]NOT in gene-target list
DiacereinNOT in gene-target list
ABP-745NOT in gene-target list
D-0120NOT in gene-target list
AzathioprineNOT in gene-target list
Colchicine (Colcrys®)NOT in gene-target list
DYV700NOT in gene-target list
dotinurad + allopurinolNOT in gene-target list
Metformin
SHR4640
tart cherry citrate effervescent tableNOT in gene-target list
Arhalofenate 600 mgNOT in gene-target list
Arhalofenate 800 mgNOT in gene-target list
Genakumab Injection (T, Solution for injection)NOT in gene-target list
Genakumab for Injection (R, Powder for solution for injection)NOT in gene-target list
XNW3009NOT in gene-target list
Febuxostat XRNOT in gene-target list
Tart cherry extract 60 mLNOT in gene-target list
Tart cherry extract 120 mLNOT in gene-target list
SAP-001NOT in gene-target list
Sodium Bicarbonate Oral CapsuleNOT in gene-target list
Potassium Citrate TabletsNOT in gene-target list
uric-acid-lowering drugNOT in gene-target list
Empagliflozin 10 mgNOT in gene-target list
Burdock ( Arctium lappa L.) root extract in a form of a nutritional additiveNOT in gene-target list
Low-dose colchicineNOT in gene-target list
Naproxen 750 mg/250 mgNOT in gene-target list
TranilastNOT in gene-target list
Combination - Tranilast and AllopurinolNOT in gene-target list
400 mg AllopurinolNOT in gene-target list
High dose combinationNOT in gene-target list
lesinurad (RDEA594)NOT in gene-target list
verinurad (RDEA3170)NOT in gene-target list
LC350189 200mgNOT in gene-target list
Moxifloxacin 400mgNOT in gene-target list
LC350189 600mgNOT in gene-target list
Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.